Answers are grounded in this paper and cite their sources.
Background Topical JAK inhibitors and calcineurin inhibitors (TCIs) are used in vitiligo management; however, their relative efficacy and safety have not been compared within a unified network meta-analysis. Objective To compare the efficacy and safety of topical JAK inhibitors and topical calcineurin inhibitors against vehicle placebo in vitiligo. Methods Six databases were searched through April 2026. Eight randomized controlled trials (950 participants) were included. Outcomes of interest were ≥50% and ≥75% reductions in Total or Facial Vitiligo Area Scoring Index (T-VASI50/75; F-VASI50/75) and adverse events. A frequentist network meta-analysis was performed using the netmeta and dmetar packages in R software. Results Ruxolitinib 1.5% cream ranked highest for total body repigmentation (T-VASI50: RR = 3.86, 95% CI: 2.24–6.66, p < 0.001; T-VASI75: RR = 3.18, 95% CI: 1.12–9.05, p = 0.030) and was the only intervention significantly superior to placebo for both endpoints. Tacrolimus 0.1% ointment ranked highest for facial repigmentation (F-VASI50/75), though estimates were imprecise since are derived from a single trial and carried wide confidence intervals. Tofacitinib 2% cream demonstrated the most favorable adverse event profile. Conclusion Ruxolitinib 1.5% cream demonstrates superior total body repigmentation, while tacrolimus 0.1% ointment shows higher estimated facial efficacy. Tofacitinib 2% cream offered the most favorable safety profile among active interventions. Large head-to-head trials are warranted to optimize clinical guidelines. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261382552 , PROSPERO CRD420261382552.
No takes yet. Share an insight, caveat, or question.
Alzhrani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: